Ali Rezaie
Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Bardia Taghavi Bayat
Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Abdollahi
Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
ABSTRACT
Fistulas, occurring in about 20 to 40% of Crohn’s disease patients, are usually resistant to conventional therapy of CD. Biologic therapies, which have revolutionary beneficial effects on diseases with an immunologic background, are a new horizon in treating fistulizing CD. The aim of this study was to evaluate the efficacy of biologic agents used to treat fistulizing CD after a brief overview on epidemiology and pathophysiology of fistulizing CD and definition of biologic therapy. Also it focuses on the trials and adverse effects of the biologic agents proved to be effective (Infliximab and CDP571).
PDF References
How to cite this article
Ali Rezaie, Bardia Taghavi Bayat and Mohammad Abdollahi, 2005. Biologic Management of Fistulizing Crohn’s Disease. International Journal of Pharmacology, 1: 17-24.
DOI: 10.3923/ijp.2005.17.24
URL: https://scialert.net/abstract/?doi=ijp.2005.17.24
DOI: 10.3923/ijp.2005.17.24
URL: https://scialert.net/abstract/?doi=ijp.2005.17.24
REFERENCES
- Farmer, R.G., W.A. Hawk and R.B. Jr. Turnbull, 1975. Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology, 68: 627-635.
PubMedDirect Link - Lapidus, A., O. Bernell, G. Hellers and R. Lofburg, 1998. Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients. Gastroenterology, 114: 1151-1160.
CrossRefDirect Link - Sands, B.E., F.H. nderson, C.N. Bernstein, W.Y. Chey and B.G. Feagan et al., 2004. Infliximab maintenance therapy for fistulizing crohn's disease. N. Engl. J. Med., 350: 876-885.
Direct Link - Sachar, D.B., 1995. Maintenance therapy in ulcerative colitis and Crohn's disease. J. Clin. Gastroenterol., 20: 117-122.
Direct Link - Sandborn, W.J. and S.R. Targan, 2002. Biologic therapy of inflammatory bowel disease. Gastroenterology, 122: 1592-1608.
PubMedDirect Link - Sandborn, W.J. and S.B. Hanauer, 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety. Inflammat. Bowel Dis., 5: 119-133.
PubMedDirect Link - Papadakis, K.A. and S.R. Targan, 2000. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology, 119: 1148-1157.
PubMedDirect Link - Podolsky, D.K., 2002. Medical progress: Inflammatory bowel disease. N. Engl. J. Med., 347: 417-429.
Direct Link - Elson, C.O., 2002. Genes, microbes and T cells new therapeutic targets in Crohn's disease. N. Engl. J. Med., 346: 614-616.
Direct Link - Keane, J., H.G. Remold and H. Kornfeld, 2000. Virulent mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol., 164: 2016-2020.
PubMedDirect Link - Sandborn, W.J., S.B. Hanauer, S. Katz, M. Safdi and D.G. Wolf et al., 2001. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology, 121: 1088-1094.
PubMedDirect Link - Schreiber, S., P. Rutgeerts, R. Fedorak, M. Khaliq-Kareemi, M.A. Kamm and J. Patel, 2003. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's Disease (CD). Gastroenterology, 124: A61-A61.
Direct Link - Sandborn, W.J., B.G. Feagan and S.B. Hanauer, D.H. Present and L.R. Sutherland et al., 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology, 120: 1330-1338.
PubMedDirect Link - Shen, C., P. Maerten, G. van Assche, K. Geboes, P. Rutgeerts and J. Ceuppens, 2004. A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocytes and T cells. Gastroenterology, 126: A153-A153.
Direct Link - Mannon, P., I. Fuss, L. Mayer, C.O. Elson and W.J. Sandborn et al., 2004. Anti-interleukin-12 treats active Crohn's disease. N. Engl. J. Med., 351: 2069-2079.
PubMedDirect Link - Hommes, D., T. Mikhajlova, S. Stoinov, D. Stimac and B. Vucelic et al., 2004. Fontolizumab (HuZAFJ), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's Disease Gastroenterology, 127: 332-332.
Direct Link - Ito, H., M. Takazoe, Y. Fukuda, H. Toshifumi and K. Kazuo et al., 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology, 126: 989-996.
CrossRefDirect Link - Ghosh, S., E. Goldin, F.H. Gordon, M.A. Helmut and M.A. Helmut et al., 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med., 348: 24-32.
Direct Link - Dieckgraefe, B.K., 2003. Sargramostim (Leukine) induces response and remission in moderately to severely activated Crohn's Disease: Results from the first randomized double-blind placebo-controlled trial. Proceedings of the 68th Annual Scientific Meeting of American College of Gastroenterology, Oct. 14-14, Baltimore, Maryland.
- Weinstock, J.V., R. Summers and D.E. Elliott, 2004. Helminths and harmony. Gut, 53: 7-9.
CrossRefDirect Link - Van Deventer, S.J.H., 1997. Tumour necrosis factor and Crohn's disease. Gut, 40: 443-448.
PubMedDirect Link - Brynskov, J., O.H. Nielsen, I. Ahnfelt-Ronne and K. Bendtzen, 1994. Cytokines (Immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig. Dis., 12: 290-304.
CrossRefDirect Link - Braegger, C.P., S. Nicholls, S.H. Murch, T.T. MacDonald and S. Stephens, 1992. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339: 89-91.
CrossRefDirect Link - Reimund, J.M., C. Wittersheim, S. Dumont, C.D. Muller, R. Baumann, P. Poindron and B. Duclos, 1996. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J. Clin. Immunol., 16: 144-150.
CrossRefDirect Link - Breese, E.J., C.A. Michie, S.W. Nicholls, S.H. Murch and C.B. Williams et al., 1994. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology, 106: 1455-1466.
Direct Link - Knight, D.M., H. Trinh, J. Le, S. Siegel and D. Shealy et al., 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol., 30: 1443-1453.
PubMedDirect Link - Scallon, B.J., M.A. Moore, H. Trinh, D.M. Knight and J. Ghrayeb, 1995. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine, 7: 251-259.
CrossRefDirect Link - Siegel, S.A., D.J. Shealy, M.T. Nakada, J. Le and D.S. Woulfe et al., 1995. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine, 7: 15-25.
PubMedDirect Link - Van den Brande, J.M., H. Braat, G.R. van den Brink, H.H. Versteeg and C.A. Bauer et al., 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 124: 1774-1785.
PubMedDirect Link - Present D.H., P. Rutgeerts, S. Targan, S.B. Hanauer and L. Mayer et al., 1999. Infliximab for the treatment of fistulas in patients with Crohn`s disease. N. Engl. J. Med., 340: 1398-1405.
Direct Link - Regueiro, M. and H. Mardini, 2003. Treatment of perianal fistulizing Crohn`s disease with infliximab alone or as an adjunct for exam under anesthesia with seton placement. Inflammat. Bowel Dis., 9: 98-103.
PubMedDirect Link - Koganei, K., A. Sugita, H. Harada, T. Fukushima and H. Shimada, 1995. Seton treatment for perianal Crohn's fistulas. Surg. Today, 25: 32-36.
CrossRefDirect Link - Hanauer, S.B., B.G. Feagan, G.R. Lichtenstein, L.F. Mayer and S. Schreiber et al., 2002. ACCENT I study group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet, 359: 1541-1549.
PubMedDirect Link - Colombel, J.F., E.V. Loftus Jr, W.J. Tremaine, L.J. Egan and W.S. Harmsen et al., 2004. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology, 126: 19-31.
PubMedDirect Link - Farrell, R.J., S.A. Shah, P.J. Lodhavia, M. Alsahli, K.R. Falchuk, P. Michetti and M.A. Peppercorn, 2000. Clinical experience with infliximab therapy in 100 patients with Crohn`s disease. Am. J. Gastroenterol., 95: 3490-3497.
PubMedDirect Link - Mohan, N., E.T. Edwards, T.R. Cupps, P.J. Oliverio and G. Sandberg et al., 2001. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum, 44: 2862-2869.
Direct Link - Tartaglia, L.A. and D.V. Goeddel, 1992. Two TNF receptors. Immunol. Today, 13: 151-153.
PubMedDirect Link - Fratazzi, C., R.D. Arbeit, C. Carini and H.G. Remold, 1997. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J. Immunol., 158: 4320-4327.
Direct Link - Keane, J., S. Gershon, R.P. Wise, E. Mirabile-Levens and J. Kasznica et al., 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med., 345: 1098-1104.
Direct Link - Feagan, B.G., W.J. Sandborn, J. Baker, F. Cominelli and L.R. Sutherland et al., 2000. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology, 118: A655-A655.
- Sandborn, W.J., B.G. Feagan and S.B. Hanauer, D.H. Present and L.R. Sutherland et al., 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology, 120: 1330-1338.
PubMedDirect Link - Jahanshahi, G., V. Motavasel, A. Rezaie, A.A. Hashtroudi, N.E. Daryani and M. Abdollahi, 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci., 49: 1752-1757.
CrossRefPubMedDirect Link